Elan Corp. (NYSE: ELN) is a neuroscience-based technology company focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases and severe pain.
Analysts sees 33-40% revenue growth for Elan in 2008 after likely 30-35% growth in 2007.
Analysts also like Elan's ramping sales for drug Tysabri for multiple sclerosis and Crohn's disease; they are also hopeful about the company's Alzheimer drug, bapineuzmab, currently in trials.
Meanwhile, margins will remain strong in 2008, but may narrow somewhat from 2007's 56%. The Reuters F2007/F2008 EPS consensus estimates for ELN are -$0.67 / -$0.28.
The risks? Reduced demand or renewed safety concerns for Tysabri would (obviously) hurt ELN's results.
The First Call mean rating for ELN is: Hold. [22 firms.] Mean 2008 target: $22.00. [high: $31, low: $12.]
Stock Analysis: Elan is a high-risk stock not suitable for moderate-risk or low-risk investors. Investors with an investment horizon longer than three years should be rewarded from ELN's shares. Sell / Stop Loss if you were to purchase shares in this company: $16.
Disclosure: Lazzaro has no positions in stocks. In addition to private real estate holdings, he owns corporate and municipal bonds, and cash certificates of deposit.
Holiday hiring slow for retailers
Closing Bell: What sell-off? (AIG, ABK, EPR, MBI, JAVA, ORCL, ERTS)
Chasing Value: 2009 blazing picks -- Q3 review 
